{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:55:08Z","timestamp":1777564508212,"version":"3.51.4"},"reference-count":15,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Foundation of CSCO-Shiyao","award":["Y-SY201901-0068"],"award-info":[{"award-number":["Y-SY201901-0068"]}]},{"name":"Foundation of CSCO-Shiyao","award":["2022M723207"],"award-info":[{"award-number":["2022M723207"]}]},{"name":"Foundation of CSCO-Shiyao","award":["2023KY666"],"award-info":[{"award-number":["2023KY666"]}]},{"name":"Cultivation of High-Level Innovative Health Talents","award":["Y-SY201901-0068"],"award-info":[{"award-number":["Y-SY201901-0068"]}]},{"name":"Cultivation of High-Level Innovative Health Talents","award":["2022M723207"],"award-info":[{"award-number":["2022M723207"]}]},{"name":"Cultivation of High-Level Innovative Health Talents","award":["2023KY666"],"award-info":[{"award-number":["2023KY666"]}]},{"name":"China Postdoctoral Science Foundation","award":["Y-SY201901-0068"],"award-info":[{"award-number":["Y-SY201901-0068"]}]},{"name":"China Postdoctoral Science Foundation","award":["2022M723207"],"award-info":[{"award-number":["2022M723207"]}]},{"name":"China Postdoctoral Science Foundation","award":["2023KY666"],"award-info":[{"award-number":["2023KY666"]}]},{"name":"Medical Scientific Research Foundation of Zhejiang Province of China","award":["Y-SY201901-0068"],"award-info":[{"award-number":["Y-SY201901-0068"]}]},{"name":"Medical Scientific Research Foundation of Zhejiang Province of China","award":["2022M723207"],"award-info":[{"award-number":["2022M723207"]}]},{"name":"Medical Scientific Research Foundation of Zhejiang Province of China","award":["2023KY666"],"award-info":[{"award-number":["2023KY666"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: B3 type thymoma is defined as a well-differentiated thymic carcinoma and is similar to a thymic carcinoma. However, the differences between them are not well defined. In addition, the data to compare the efficacy and safety of platinum-based chemotherapy as first-line therapy between B3 thymoma and thymic carcinoma are lacking. Methods: The efficacy and safety of platinum-based chemotherapy as first-line therapy was retrospectively compared between a group of 36 patients with type B3 thymoma and a group of 127 patients with thymic carcinoma treated between January 2009 and March 2022 at the Zhejiang Cancer Hospital. Objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events were analyzed. Results: The ORRs for B3 thymoma and thymic carcinoma were 36.1% and 28.3%, respectively (p = 0.370). Among all patients, the difference in PFS between B3 thymoma and thymic carcinoma was not significant (11.3 vs. 10.1 months, p = 0.118). The squamous carcinoma subgroup did not exhibit any differences in PFS compared to B3 thymoma (11.7 vs. 11.3 months, p = 0.161). The result for the non-squamous carcinoma subgroup was similar (6.5 vs. 11.3 months, p = 0.128). Furthermore, the OS values for B3 thymoma and thymic carcinoma were not significantly different (58.3 vs. 35.1 months, p = 0.067). However, there were differences in OS between B3 thymoma and non-squamous carcinoma (58.3 vs. 30.6 months, p = 0.031). Conclusions: B3 thymoma and especially squamous carcinoma patients may be treated using a similar therapy scheme as that utilized for thymic carcinoma.<\/jats:p>","DOI":"10.3390\/curroncol29120743","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T11:02:10Z","timestamp":1670238130000},"page":"9452-9460","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy between B3 Thymoma and Thymic Carcinoma"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4725-6084","authenticated-orcid":false,"given":"Yue","family":"Hao","sequence":"first","affiliation":[{"name":"The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou 310000, China"},{"name":"Department of Clinical Trial, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou 310022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6351-1690","authenticated-orcid":false,"given":"Jinfei","family":"Si","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou 310000, China"},{"name":"Department of Clinical Trial, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou 310022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9903-9276","authenticated-orcid":false,"given":"Jianan","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Clinical Trial, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou 310022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwen","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Clinical Trial, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou 310022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xiang","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou 310000, China"},{"name":"Department of Clinical Trial, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou 310022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9021-6731","authenticated-orcid":false,"given":"Chunwei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210093, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengbo","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Clinical Trial, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou 310022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ejca.2012.02.047","article-title":"Rare thoracic cancers, including peritoneum mesothelioma","volume":"48","author":"Siesling","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.critrevonc.2016.01.012","article-title":"Thymoma and thymic carcinomas","volume":"99","author":"Scorsetti","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.21037\/atm.2020.02.183","article-title":"Development of a deep learning model for classifying thymoma as Masaoka-Koga stage I or II via preoperative CT images","volume":"8","author":"Yang","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","article-title":"Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors","volume":"29","author":"Giaccone","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.lungcan.2018.10.018","article-title":"Systemic treatments for thymoma and thymic carcinoma: A systematic review","volume":"126","author":"Berghmans","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11864-009-0083-7","article-title":"Treatment of advanced thymoma and thymic carcinoma","volume":"9","author":"Rajan","year":"2008","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4","article-title":"Chemotherapy for invasive thymoma. A 13-year experience","volume":"68","author":"Fornasiero","year":"1991","journal-title":"Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.jtho.2018.08.005","article-title":"Systemic therapy in advanced thymic epithelial tumors: Insights from the RYTHMIC prospective cohort","volume":"13","author":"Dansin","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/annonc\/mdu541","article-title":"A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L","volume":"26","author":"Hirai","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.21037\/med-20-62","article-title":"The role of immunotherapy for management of advanced thymic epithelial tumors: A narrative review","volume":"5","author":"Rajan","year":"2021","journal-title":"Mediastinum"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s11864-009-0084-6","article-title":"The World Health Organization (WHO) histologic classification of thymomas: A reanalysis","volume":"9","author":"Moran","year":"2008","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1002\/cncr.23492","article-title":"Evidence-based pathology and the pathologic evaluation of thymomas: The World Health Organization classification can be simplified into only 3 categories other than thymic carcinoma","volume":"112","author":"Marchevsky","year":"2008","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejcts.2009.05.038","article-title":"Thymoma and thymic carcinoma","volume":"37","author":"Venuta","year":"2010","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"102133","DOI":"10.1016\/j.ctrv.2020.102133","article-title":"Pathological and clinical features of enteric adenocarcinoma of the thymus. A pooled analysis of cases from a reference center and systematic review of the literature","volume":"92","author":"Conforti","year":"2021","journal-title":"Cancer Treat. Rev."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/12\/743\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:33:13Z","timestamp":1760146393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/12\/743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":15,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["curroncol29120743"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29120743","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,2]]}}}